Luis M Branco

List of Publications by Year
in descending order

34	1,554	394421 19	477307 29
papers	citations	h-index	g-index

34	34	34	1823
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Delineating the mechanism of anti-Lassa virus GPC-A neutralizing antibodies. Cell Reports, 2022, 39, 110841.	6.4	17
2	Neutralizing Antibodies against Lassa Virus Lineage I. MBio, 2022, 13, .	4.1	12
3	Space-Time Trends in Lassa Fever in Sierra Leone by ELISA Serostatus, 2012â€“2019. Microorganisms, 2021, 9, 586.	3.6	10
4	Successful Clearance of 300 Day SARS-CoV-2 Infection in a Subject with B-Cell Depletion Associated Prolonged (B-DEAP) COVID by REGEN-COV Anti-Spike Monoclonal Antibody Cocktail. Viruses, 2021, 13, 1202.	3.3	26
5	Cross-Reactive Antibodies to SARS-CoV-2 and MERS-CoV in Pre-COVID-19 Blood Samples from Sierra Leoneans. Viruses, 2021, 13, 2325.	3.3	24
6	Antibodies from Sierra Leonean and Nigerian Lassa fever survivors cross-react with recombinant proteins representing Lassa viruses of divergent lineages. Scientific Reports, 2020, 10, 16030.	3.3	15
7	From Kenema to Our Krios: Medical Defense Against Lassa Virus and Emerging Infectious Disease. Microscopy and Microanalysis, 2020, 26, 568-568.	0.4	0
8	High crossreactivity of human T cell responses between Lassa virus lineages. PLoS Pathogens, 2020, 16, e1008352.	4.7	22
9	Identification of Common CD8⁺T Cell Epitopes from Lassa Fever Survivors in Nigeria and Sierra Leone. Journal of Virology, 2020, 94, .	3.4	15
10	Field evaluation of a Pan-Lassa rapid diagnostic test during the 2018 Nigerian Lassa fever outbreak. Scientific Reports, 2020, 10, 8724.	3.3	14
11	Ebola-Specific CD8+ and CD4+ T-Cell Responses in Sierra Leonean Ebola Virus Survivors With or Without Post-Ebola Sequelae. Journal of Infectious Diseases, 2020, 222, 1488-1497.	4.0	13
12	High crossreactivity of human T cell responses between Lassa virus lineages. , 2020, 16, e1008352.		0
13	High crossreactivity of human T cell responses between Lassa virus lineages. , 2020, 16, e1008352.		0
14	High crossreactivity of human T cell responses between Lassa virus lineages. , 2020, 16, e1008352.		0
15	High crossreactivity of human T cell responses between Lassa virus lineages. , 2020, 16, e1008352.		0
16	Convergent Structures Illuminate Features for Germline Antibody Binding and Pan-Lassa Virus Neutralization. Cell, 2019, 178, 1004-1015.e14.	28.9	39
17	Antibody therapy for Lassa fever. Current Opinion in Virology, 2019, 37, 97-104.	5.4	28
18	Field validation of recombinant antigen immunoassays for diagnosis of Lassa fever. Scientific Reports, 2018, 8, 5939.	3.3	39

#	Article	IF	Citations
19	Host Proteins Identified in Extracellular Viral Particles as Targets for Broad-Spectrum Antiviral Inhibitors. Journal of Proteome Research, 2018, 18, 7-17.	3.7	7
20	Analysis of CD8 ⁺ T cell response during the 2013â€“2016 Ebola epidemic in West Africa. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E7578-E7586.	7.1	55
21	Annual Incidence of Lassa Virus Infection in Southern Mali. American Journal of Tropical Medicine and Hygiene, 2017, 96, 16-0821.	1.4	14
22	Structural basis for antibody-mediated neutralization of Lassa virus. Science, 2017, 356, 923-928.	12.6	170
23	Human-monoclonal-antibody therapy protects nonhuman primates against advanced Lassa fever. Nature Medicine, 2017, 23, 1146-1149.	30.7	95
24	Lassa Virus Seroprevalence in Sibirilia Commune, Bougouni District, Southern Mali. Emerging Infectious Diseases, 2016, 22, 657-663.	4.3	26
25	An Outbreak of Ebola Virus Disease in the Lassa Fever Zone. Journal of Infectious Diseases, 2016, 214, S110-S121.	4.0	34
26	Most neutralizing human monoclonal antibodies target novel epitopes requiring both Lassa virus glycoprotein subunits. Nature Communications, 2016, 7, 11544.	12.8	148
27	Treatment of Lassa virus infection in outbred guinea pigs with first-in-classÂhuman monoclonal antibodies. Antiviral Research, 2016, 133, 218-222.	4.1	57
28	Clinical Sequencing Uncovers Origins and Evolution of Lassa Virus. Cell, 2015, 162, 738-750.	28.9	230
29	Lassa Fever in Post-Conflict Sierra Leone. PLoS Neglected Tropical Diseases, 2014, 8, e2748.	3.0	172
30	Geographic Distribution and Genetic Characterization of Lassa Virus in Sub-Saharan Mali. PLoS Neglected Tropical Diseases, 2013, 7, e2582.	3.0	49
31	Capacity building permitting comprehensive monitoring of a severe case of Lassa hemorrhagic fever in Sierra Leone with a positive outcome: Case Report. Virology Journal, 2011, 8, 314.	3.4	41
32	Emerging trends in Lassa fever: redefining the role of immunoglobulin M and inflammation in diagnosing acute infection. Virology Journal, 2011, 8, 478.	3.4	69
33	Detection of Lassa Virus, Mali. Emerging Infectious Diseases, 2010, 16, 1123-1126.	4.3	89
34	Bacterial-based systems for expression and purification of recombinant Lassa virus proteins of immunological relevance. Virology Journal, 2008, 5, 74.	3.4	24